BRIEF-Bank of Hawaii says Kent Lucien to be chief strategy officer
* Says Kent T. Lucien, vice chair, currently Bank of Hawaii's chief financial officer, will become chief strategy officer
FRANKFURT Oct 1 German biotech Morphosys moved a step closer to getting its first antibody drug onto the market as its licensee, Johnson & Johnson unit Jenssen, reported positive results from a phase 3 study of psoriasis drug guselkumab.
Johnson & Johnson said earlier the experimental biotech drug proved more effective at clearing moderate to severe cases of the skin condition than a placebo or Abbvie's Humira, the world's top-selling prescription medicine.
A Morphosys spokesman said on Saturday that guselkumab could now become its first drug to market, depending on whether and when Johnson & Johnson makes an application.
Morphosys gets milestone payments during the development phase and would receive royalties from Johnson & Johnson once it goes on sale.
It has another drug in phase 3 study with Roche, for Alzheimer's disease, and one in phase 2 - which in this case is likely to be the final phase - with Bayer, for asbestos-related lung cancer.
(Reporting by Georgina Prodhan)
* Says that Apple's claims are baseless Source text for Eikon: Further company coverage:
Jan 20 Apple Inc filed a $1 billion lawsuit against supplier Qualcomm Inc on Friday, days after the U.S. government accused the chip maker of resorting to anticompetitive tactics to maintain a monopoly over key semiconductors in mobile phones.